In fact, several studies demonstrated that adropin levels are lower in humans with obesity, type 2 diabetes, insulin resistance, hepatic steatosis/NAFLD, polycystic ovary syndrome (PCOS), and cardiovascular diseases [22]. This evidence concerns the gene ENHO and metabolic dysfunction-associated steatotic liver disease.